Poseida Therapeutics Nominates a New CAR-T Development Candidate Under Partnership with Roche
Shots:
- Poseida Therapeutics has nominated a new CAR-T candidate for development as per an agreement signed with Roche in Aug 2022, triggering a milestone payment of $15M
- The new allogeneic dual CAR-T candidate will target antigens in hematologic cancers like multiple myeloma. Poseida's non-viral transposon-based DNA delivery system enables the transfer of two full-length CAR genes into T stem cell memory cells
- Poseida and Roche now include 3 CAR-T programs under their partnership focusing on hematologic malignancies, with the lead candidate, P-BCMA-ALLO1 (targeting BCMA), being in P-Ib study for r/r multiple myeloma & the second one, P-CD19CD20-ALLO1, being in P-I trial for B-cell malignancies
Ref: Poseida Therapeutics | Image: Poseida Therapeutics and Roche
Related News:- Poseida Therapeutics’ P-BCMA-ALLO1 Gains the US FDA’s Regenerative Medicine Advanced Therapy Designation for R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
